Analysis of IHC Quantification
This technology provides a diagnostic framework to discriminate between the early and late stages of Barrett’s esophagus by testing a biological sample for expression of specific proteins, comparing the amount of those proteins to reference values. The researchers have created prototypes of diagnostic kits for making these protein determinations.
Application & Market Utility
It’s hard to diagnose Barrett’s esophagus (BE) as either low (LGD) or high grade dysplasia (HGD). HGD carries an increased risk of esophageal adenocarcinoma so gastroenterologists aggressively treat it, while LGD patients remain on active surveillance. Misdiagnosis could be fatal. Currently, no accurate markers are used clinically and the diagnosis of BE is still based on histopathology of the biopsy. This technology is useful to producers of diagnostic kits, suppliers to pathologists, and gastroenterologists.
Seeking research collaboration and licensing opportunities.